|
| REVIEW ARTICLE |
 |
|
|
| Year : 2018 |
Volume
: 11 | Issue : 2 | Page
: 119-124 |
|
Urinary versus recombinant gonadotropins for ovarian stimulation in women undergoing treatment with assisted reproductive technology
Ameet Patki1, Himanshu Bavishi2, Chandravati Kumari3, Jayarani Kamraj4, M Venugopal5, KU Kunjimoideen6, Poornima Nadkarni7, Samundi Sankari8, Sunil Chaudhary9, MJ Sangeeta10, CS Manjunath11, Pratap Kumar12
1 Department of Reproductive Endocrinology, Fertility Associates, Mumbai, Maharashtra, India
2 Department of Reproductive Endocrinology, Bavishi Fertility Institute, Ahmedabad, Gujarat, India
3 Krishna Medical Center, Lucknow, Uttar Pradesh, India
4 Aakash Fertility Centre and Hospital, Chennai, Tamil Nadu, India
5 ARMC IVF, Thrissur, Kerala, India
6 ARMC IVF, Kozhikode, Kerala, India
7 Department of IVF, Nadkarni Hospital and 21st Century Hospitals, Surat, Gujarat, India
8 Srushti Fertility Centre, Chennai, Tamil Nadu, India
9 Jammu Centre for Human Reproduction, Jammu, Jammu and Kashmir, India
10 Caree Fertility Centre, Bengaluru, Karnataka, India
11 Mathrutva Fertility Center, Bengaluru, Karnataka, India
12 Department of Obstetrics and Gynaecology, Kasturba Medical College, Manipal, Karnataka, India
Correspondence Address:
Dr. Ameet Patki
Fertility Associates 81, 4th Floor, Gupte House, S.V. Road, Near Khar Police Station, Khar West, Mumbai, Maharashtra - 400 052
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jhrs.JHRS_79_17
|
|
|
Globally, about 10%–15% couples are affected by infertility, with major role being played by the couple's lifestyle. Several gonadotropin preparations (urinary, purified urinary, recombinant, and biosimilars) are available for use. Purified urinary formulations offer numerous advantages over their predecessor, including lesser injection dose required, ability to be administered subcutaneously, less batch-to-batch variability, better efficacy, ability to individualize protocols as per patient's need, better control of developing follicles, less risk of multiple pregnancies, and hyperstimulation. Published results of Cochrane reviews and meta-analysis show no difference in efficacy or safety between urinary and recombinant gonadotropins. In the absence of any significant difference, cost plays an important role in deciding choice of gonadotropins. In this article, we have reviewed the results of comparative clinical trials, Cochrane analysis, and meta-analysis to derive consensus statements regarding efficacy, safety, and cost implications of urinary versus recombinant gonadotropin preparations.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
|
|
| Article Access Statistics | | | Viewed | 4761 | | | Printed | 115 | | | Emailed | 0 | | | PDF Downloaded | 276 | | | Comments | [Add] | | | Cited by others | 2 | | |
|
|
